How has been the historical performance of Concord Drugs?

Answer:The historical performance of Concord Drugs shows a decline in net sales and profitability over the past four years.

Breakdown:
Concord Drugs experienced a decrease in net sales from 59.06 Cr in March 2022 to 45.25 Cr in March 2025, with a slight increase from 44.93 Cr in March 2024. The total operating income followed a similar trend, dropping from 59.06 Cr in March 2022 to 45.25 Cr in March 2025. The company's total expenditure, excluding depreciation, also decreased from 53.37 Cr in March 2022 to 41.11 Cr in March 2025. Operating profit (PBDIT) declined from 5.69 Cr in March 2022 to 4.14 Cr in March 2025, while profit before tax fell from 2.25 Cr to 0.69 Cr in the same period. Profit after tax showed a similar decline, decreasing from 1.59 Cr in March 2022 to 0.34 Cr in March 2025. The earnings per share (EPS) dropped from 1.82 in March 2022 to 0.34 in March 2025. On the balance sheet, total assets increased from 56.45 Cr in March 2022 to 65.14 Cr in March 2025, while total liabilities also rose from 56.45 Cr to 65.14 Cr. The company's cash flow from operating activities improved to 3.00 Cr in March 2025, compared to 1.00 Cr in March 2023, but the overall cash flow remained stagnant with no net cash inflow or outflow reported.